Omega Healthcare Investors, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OHI research report →
Range $46 – $56
Price Chart
About the company
Omega Healthcare Investors, Inc. functions as a Real Estate Investment Trust (REIT) primarily focused on the long-term healthcare sector. The company strategically invests in properties providing skilled nursing and assisted living services.
- CEO
- Matthew Gourmand
- IPO
- 1992
- Employees
- 69
- HQ
- Hunt Valley, MD, US
Get TickerSpark's AI analysis on OHI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.86B
- P/E
- 18.61
- Fwd P/E
- 17.81
- PEG
- 0.50
- P/S
- 10.85
- P/B
- 2.60
- EV/EBITDA
- 13.66
- Div Yield
- 5.73%
- Gross Margin
- 70.57%
- Op Margin
- 54.60%
- Net Margin
- 57.66%
- ROE
- 14.32%
- ROIC
- 7.24%
Latest fiscal year · YoY change
- Revenue
- $1.20B+14.0%
- Gross Profit
- $533.17M-48.6%
- Op Income
- $749.44M
- Net Income
- $590.11M+45.2%
- EPS
- $2.02+28.7%
- OCF Growth
- +17.2%
- FCF Growth
- +23.4%
- 52W High
- $52.39
- 52W Low
- $42.18
- 50D MA
- $46.41
- 200D MA
- $46.88
- Beta
- 0.55
- RSI (14)
- 43
- Avg Volume
- 2.02M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Omega delivered solid third-quarter AFFO/FAD and raised full-year guidance, while highlighting accretive portfolio moves, strong liquidity, and continued capital deployment across the U.S. and U.K.· November 4, 2026
- Q3 adjusted FFO was $0.82 per share and FAD was $0.78 per share, with management saying the quarter was solid but sequentially flat because of late-Q2 asset sales.
- Omega raised and tightened 2026 adjusted FFO guidance to $3.28-$3.30 per share, up from $3.22-$3.26, with a new midpoint of $3.29.
- The company completed a major transition of 32 Florida facilities to PACS, adding $26.1 million of first-year annual cash rent and implying about $0.065 per share of annualized FAD accretion.
- Genesis was resolved through a chapter 11 sale, with Omega preserving lease economics, repaying its DIP loan, and receiving a $150 million term loan from NewGen.
- Management emphasized active portfolio management, a strong pipeline, and low leverage, and said it remains focused on disciplined capital allocation rather than loans for their own sake.
Third-quarter 2026 revenue was $341 million, up from $312 million in Q3 2025. Net income available to common shareholders was $83 million, or $0.27 per diluted share, versus $180 million, or $0.59 per diluted share a year ago, with the decline driven mainly by $60 million of acquisition, merger and transition-related expenses and a $28 million gain on asset sales in the prior year. Q3 adjusted FFO was $262 million, or $0.82 per share, and FAD was $250 million, or $0.78 per share. On the portfolio side, trailing 12-month operator EBITDAR coverage improved to 1.67x from 1.65x, and occupancy edged up to 82.7% from 82.6%. The company raised full-year 2026 adjusted FFO guidance to $3.28-$3.30 per share from $3.22-$3.26, with a midpoint of $3.29. Guidance assumes the newly announced investments through November 3, the PACS transition, no additional assets or transactions beyond those disclosed, and quarterly G&A of about $14 million to $15.5 million. At quarter end, Omega had no revolver borrowings, $196 million in cash, a 6.9x fixed charge coverage ratio, and leverage of 3.1x.
Matthew Gourmand struck an optimistic, execution-focused tone and framed the quarter as evidence of Omega’s ability to create long-term value through portfolio reshaping rather than simply collecting rent. He highlighted the 7 cap rate asset sales, the 29% effective yield on the PACS transition, and more than $1 billion deployed in the second half of the year to date, saying these moves improve credit support and create accretive growth. He also emphasized that Omega is disciplined on capital allocation, has an excellent cost of capital, and is focused on strong operators, quality real estate, and sustainable returns.
Neal Alexander Ballew walked through the quarter’s financial bridge, noting that Q3 AFFO per share was down about $0.01 sequentially because roughly $775 million of asset sales and loan repayments over the past two quarters reduced AFFO by $8.8 million. That was partly offset by income from $308 million of new investments, $124 million of Sabre PropCo JV activity, and about $5 million of lower net interest expense. He also pointed to a strong balance sheet with $196 million of cash, no revolver borrowings, a 6.9x fixed charge coverage ratio, and leverage at 3.1x, and said Omega is targeting leverage below 4x for the foreseeable future. On guidance, he said the raised midpoint of $3.29 per share reflects the new investments and the PACS transition, while assuming $306 million of loans outstanding at September 30 are repaid in Q4, including $150 million of Genesis loans.
Analysts focused on the Runwood U.K. mortgage deal, the PACS transition, the Genesis/NewGen restructuring, and whether the company would continue to use loan structures. Management said the Runwood transaction was marketed and competitive, that it expects to convert the mortgage to a lease in about a year after regulatory approvals, and that the initial coverage is good with upside from acuity and rate increases. On Genesis, management said the new lease economics are the same as before, NewGen will be on a straight-line basis because of better credit, and Omega would be open to more business with NewGen if things go well. On capital deployment, management said the market remains competitive, cap rates have become more aggressive, and while equity issuance or a combination of term loan and ATM proceeds could be used to manage the balance sheet, loaning money for its own sake is not a preferred strategy.
The bull case from this call is that Omega is showing it can turn portfolio management into meaningful earnings accretion, as seen in the PACS transition, Genesis resolution, and a strong U.K. investment pipeline. Management also pointed to improving coverage, strong liquidity, no revolver borrowings, and leverage of 3.1x, while raising full-year AFFO guidance and signaling room for further accretive deals.
The main risks discussed were the competitive acquisition environment, more aggressive cap rates, and the possibility that future regulatory scrutiny in long-term care could intensify over time. Management also acknowledged that some guidance depends on loan repayments, rent assumptions, and no additional operators moving to cash basis, while the U.K. and RIDEA conversions carry execution and operator-partnership risk. The company also said some assets or operators could still require active management, and future opportunities depend on finding willing counterparties at the right price.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 304.33M
- Float Shares
- 303.36M
of shares held by institutions
785 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OHI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Mar 7, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Apr 11, 22 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Nov 20, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Jul 9, 20 | Filing → |
| Billy LongHouse · MO07 | Sell | Dec 31, 20 | Filing → |
| Billy LongHouse · MO07 | Sell | Dec 31, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Nov 20, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Jul 9, 20 | Filing → |
| Van TaylorHouse · TX03 | Sell | Mar 25, 19 | Filing → |
| Van TaylorHouse · TX03 | Sell | Feb 13, 19 | Filing → |
| Susan Margaret CollinsSenate · ME | Sell | May 7, 14 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 42.16M | ▲ 7.64K |
| Blackrock, Inc. | 39.44M | ▲ 885.66K |
| Vanguard Portfolio Management LLC | 26.91M | ▼ 323.77K |
| Cohen & Steers, Inc. | 22.94M | ▲ 10.96M |
| State Street Corp | 14.97M | ▲ 440.16K |
| Vanguard Capital Management LLC | 13.60M | ▲ 165.67K |
| Geode Capital Management, LLC | 9.23M | ▲ 91.76K |
| Bank Of New York Mellon Corp | 5.44M | ▼ 336.95K |
| Charles Schwab Investment Management Inc | 4.82M | ▲ 201.77K |
| Sixth Street Partners Management Company, L.P. | 4.82M | ▲ 4.82M |
| Dimensional Fund Advisors LP | 4.70M | ▲ 284.27K |
| Norges Bank | 3.99M | ▲ 3.99M |
Held by 604 ETFs
Biggest fund positions in OHI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Golem Lucas M. | other | 1,050 |
| Sep 30, 26 | Golem Lucas M. | other | 2,776 |
| Sep 30, 26 | Golem Lucas M. | other | 2,776 |
| Sep 30, 26 | Golem Lucas M. | other | 1,050 |
| Oct 1, 26 | Golem Lucas M. | other | 64 |
| Oct 1, 26 | Golem Lucas M. | sell | 3 |
| Sep 30, 26 | PICKETT C TAYLOR | other | 26,177 |
| Sep 30, 26 | PICKETT C TAYLOR | other | 69,225 |
| Sep 30, 26 | PICKETT C TAYLOR | other | 69,225 |
| Sep 30, 26 | PICKETT C TAYLOR | other | 26,177 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OHI coverage
Recent articles, reports, and earnings notes.
No research on OHI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OHI report →5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
247wallst.com · Nov 20
A 62-Year-Old Made One Roth IRA Mistake at Retirement. Here’s What Happened to Her $4,475 Tax-Free Monthly Paycheck
247wallst.com · Nov 18
4 High-Yield Healthcare Stocks Retirees Should Buy for December Income
247wallst.com · Nov 18
3 Healthcare REITs Are Cashing In on America’s Aging Population
247wallst.com · Nov 16
5 Ultra-High-Yield Dividend Stocks Retirees Should Buy Before December
247wallst.com · Nov 16
4 High-Yield REITs Roth IRA Investors Should Own for Tax-Free Income
247wallst.com · Nov 16
PEB or OHI: Which Is the Better Value Stock Right Now?
zacks.com · Nov 13
How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free
247wallst.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.